Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers

Breast Cancer Clinical Trial

— ER  

Official title:

Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03790813
• Other study ID #: H18-02581
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 7, 2019
• Est. completion date: December 31, 2023

Study information

• Verified date: December 2018
• Source: British Columbia Cancer Agency
• Contact: Nathalie LeVasseur, MD
• Phone: 604-877-6000x2734
• Email: nathalie.levasseur[@]bccancer.bc.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the addition of Ki-67, Oncotype DX and MRI in the treatment of early stage breast cancer with neoadjuvant treatment. All enrolled patients will have Ki-67 and Oncotype AND/OR an MRI before and after surgery.

Description:

Based on what is known about the treatment of breast cancer, there are occasional advantages to giving treatment before surgery. Some of these advantages can include shrinking a large breast cancer to facilitate surgery, shrinking a breast cancer to allow breast conservation (avoid a mastectomy), and evaluating how effective a treatment is in real-time, based on its effect on the breast cancer.

When recommending treatment with hormone therapy and/or chemotherapy, doctors take into consideration all the characteristics of a breast cancer. Over recent years, is has been recognized that additional tests can help predict the behavior of a cancer and predict the possible benefit of hormone therapy and/or chemotherapy. Because there is no way to identify exactly who benefits from chemotherapy, many patients receive chemotherapy when they might not need it.

This study involves the use of 2 separate tests. The first is called Ki-67 and is done using a piece of tumour that is taken during a needle biopsy. The second, called the Oncotype DX, is made by Genomic Health, Inc, located in Redwood, CA, USA. This test also uses a piece of tumour that was retrieved during a needle biopsy. The pieces will be tested in a specialized laboratory that can measure the levels of a specific set of genes in the tumour. The laboratory that performs this test (Redwood, CA, USA) has been certified by federal and state agencies in the United States to perform the test (called Oncotype DX). The results of the test are turned into a score (called Recurrence Score) that has been used for patients receiving treatment after surgery, but has not yet been used when treatment is given before surgery.

The standard practice for this type of cancer is for the patient and their doctor to decide whether they should receive chemotherapy in addition to hormone therapy or to take hormone therapy alone, prior to surgery. The Ki-67 is inconsistently used in British Columbia prior to surgery, but may be used routinely in other centers. Usually, the Oncotype DX test is not available to aid in this decision outside of a research study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria:

1. Patient must be between the ages (inclusive) of 18-89.

2. Patient has adequate performance status (PS ECOG 0,1 or Karnofsky performance status =70) and is a medically fit candidate for treatment of their cancer with systemic chemotherapy and/or hormonal therapy with no contra-indications to both systemic therapy options.

3. Patient is medically fit enough to be a surgical candidate.

4. Patient must be able to give informed consent directly or through the assistance of an interpreter.

5. Pathological confirmation of breast cancer by core biopsy.

6. Ductal or lobular breast cancer.

7. Breast cancer with a primary tumour (clinically selected T2-T4) OR clinically node positive.

8. Breast cancer is clinically palpable either in the breast, axilla or other nodal site.

9. ER positive by IHC (Allred >=4).

10. Her2Neu negative by IHC (0 or 1+) or FISH by current ASCO/CAP guidelines.

Exclusion Criteria:

1. Patient is a male with breast cancer.

2. Patients have ER negative tumors (ER-) by local or central BCCA assessment.

3. Patients have HER2 positive tumors by local or central BCCA assessment.

4. Patients have known metastatic breast cancer or develop metastatic disease prior to surgery.

5. Patients are unable to give consent or understand written language.

6. Patients with poor performance status (ECOG 2-4) in whom consideration of neoadjuvant chemotherapy OR hormonal therapy would be contraindicated.

7. Patients who are not fit enough to be a surgical candidate.

8. Pregnant women in whom consideration of neoadjuvant chemotherapy or neoadjuvant hormonal therapy would be contraindicated.

9. Patients who receive less than 2 weeks of neoadjuvant systemic therapy.

10. Patients who have not undergone surgical resection 12 months after enrollment.

For intervention 1 only:

1. Patients with tumors that on GHI central pathological review appears inadequate for the Oncotype DX® assay.

2. Patients with tumors that on BCCA pathological review appears inadequate for Ki-67 immunohistochemistry.

For intervention 2 only:

1. Patients with a pacemaker or contra-indication to MRI.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Diagnostic Test:
• Intervention 1
Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.
• Intervention 2
MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
British Columbia Cancer Agency	Genomic Health®, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of neoajduvant Ki-67 and Oncotype DX, defined as >=75% enrollment rate for all screened patients	• Technical feasibility of obtaining Ki-67 and Oncotype DX assay from a core biopsy sample in >= 75% of samples tested, prior to the initiation of systemic treatment.	1 month
Primary	Turnaround time of Ki-67 and Oncotype DX, defined as time from patient consent to date results are obtained	Turnaround time will be defined as: Time from patient consent to reporting of the Ki-67 and Oncotype DX	1 month
Primary	Feasibility of MRI prior to neoadjuvant systemic treatment, defined as >=75% of patients who receive an MRI before the start of neoadjuvant treatment	• Practical feasibility of obtaining serial MRIs with the existing means, resources and booking circumstances in >=75% of cases prior to the initiation of systemic therapy and surgical resection	6 months
Primary	Turnaround time of MRI prior to neoadjuvant systemic treatment, defined as time from patient consent to date of 1st MRI	Turnaround time will be defined as: • Time from patient consent to pre-treatment (baseline) MRI	6 months
Secondary	Correlation of Ki-67 and Oncotype DX to each other and to the outcome of neoadjuvant systemic treatment.	To characterize how the results of the Ki-67 Oncotype DX assay relate to the outcome of neoadjuvant systemic treatment and whether the results correlate to each other (Ki-67 and Oncotype DX).	6 months
Secondary	Predictive association of Ki-67 and Oncotype to invasive locoregional or systemic relapse	• Time from study enrollment to the development of invasive locoregional or systemic breast cancer.	5 years
Secondary	Predictive association of Ki-67 and Oncotype to overall survival	• Time from enrollment to death from any cause.	5 years
Secondary	Impact of serial MRI on changes to surgical planning	Changes from original to final surgical plan.	6 months
Secondary	Correlation of serial MRI to clinical and pathological response	Characterize how the results of serial MRIs affect surgical planning and how the radiological response relates to clinical response and pathological response.	6 months
Secondary	Patient reported outcomes assessed by questionnaire	Patient reported outcomes assessed with a questionnaire exploring decisional conflict.; 9 questions are asked of patients regarding the MRI results and its impact on decision making. The scale is a 5 point scale, ranging from strongly disagree (1) to strongly agree (5). Results will be reported qualitatively.	6 months